KK
MLYS icon

KLP Kapitalforvaltning’s Mineralys Therapeutics MLYS Stock Holding History

KLP Kapitalforvaltning’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$282K Buy
10,400
+800
+8% +$23.5K ﹤0.01% 1685
2025
Q4 		$348K Buy
9,600
+2,900
+43% +$116K ﹤0.01% 1589
2025
Q3 		$254K Hold
6,700
– – ﹤0.01% 1721
2025
Q2 		$90.7K Buy
+6,700
New +$97.1K ﹤0.01% 2070

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

KLP Kapitalforvaltning's MLYS Position: Q1 2026 in Review

KLP Kapitalforvaltning increased its Mineralys Therapeutics (MLYS) stake by 8.3% in Q1 2026, buying an estimated $23.5K and bringing the position to 10,400 shares worth $282K. The position accounts for ﹤0.01% of the portfolio, ranked #1685.

KLP Kapitalforvaltning first reported a position in MLYS in Q2 2025 and has held it in 4 quarters since. The position peaked at $348K in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • KLP Kapitalforvaltning held 10,400 shares of Mineralys Therapeutics worth $282K as of Q1 2026.
  • KLP Kapitalforvaltning bought 800 Mineralys Therapeutics shares in Q1 2026, an estimated $23.5K.
  • Mineralys Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q1 2026, its #1685 holding.
  • KLP Kapitalforvaltning first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • KLP Kapitalforvaltning's Mineralys Therapeutics position peaked at $348K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q1 2026, filed 29 Apr 2026.